Summary: Osteoporosis, a systemic disease of the bones, is a serious health and socio-economic problem because of its consequences, i.e. broken bones. It is believed that 10% of the world's population suffers from osteoporosis and it affects mostly postmenopausal women (postmenopausal osteoporosis). Tibolone is a synthetic steroid that has estrogenic, androgenic, and progestagenic properties. It has been used primarily for the prevention of postmenopausal osteoporosis and treatment of climacteric symptoms. The research included a group of 40 postmenopausal women with osteopenia treated with tibolone. The control group included 40 postmeno pausal women who were not taking any medication. Control group patients were older (54.5 ± 9.84) than the patients treated with tibolone (51.6 ± 6.22). Bone meta bolic activity was evaluated using osteocalcin (N-MID osteocalcin) for bone formation and CTX I for bone resorption. Blood samples were taken before therapy was introduced and 3 months after its introduction. The average value of osteocalcin after three months of tibolone therapy was 26.32 ± 3.312 ng/mL compared to the average osteocalcin value prior to the rapy of 29.6 ± 3.343 ng/mL. The average value of CTX I three months after tibolone therapy of 0.2870 ± 0.0783 ng/mL was lower compared to the average CTX I value before the therapy of 0.4539 ± 0.1144 ng/mL. Our results show the efficacy of tibolone in preventing bone loss, which was highly statistically significant. They also reveal its suppressive effects on bone for mation and resorption, but these effects are statistically less significant. Tibolone signifKratak sadr`aj: Osteoporoza, sistemsko oboljenje kostiju, predstavlja ozbiljan zdravstveni i socijalno-ekonomski problem zbog svojih posledica, preloma kostiju. Smatra se da 10% svetske populacije boluje od osteoporoze, a posebno su ugro `ene `ene u postmenopauzi. Tibolon je tkivno specifi~an steroid sa estrogenim, progestagenim i androgenim svojstvima. Prvenstveno se koristi za prevenciju postmenopauzalne osteoporoze i ubla`avanje klimakteri~nih tegoba. Istra`ivanje je sprovedeno u grupi od 40 `ena sa osteopenijom u postmenopauzi tretiranih tibolonom. Kontrolnu grupu ~inilo je 40 `ena u postmenopauzi koje nisu uzimale nikakvu terapiju. Pacijentkinje kontrolne grupe bile su starije (54,5 ± 9,84) od pacijentkinja tretiranih tibolonom (51,6 ± 6,22). Od para metara metaboli~ke aktivnosti kosti kori{}eni su osteo kalcin kao parametar formiranja kosti i CTX I kao parametar resorpcije kosti. Krv je va|ena pre uvo|enja terapije i 3 meseca nakon uvo|enja terapije. Prose~na vrednost osteokalcina tri meseca nakon terapije tibolonom je bila ni`a (26,32 ± 3,312 ng/mL) u odnosu na prose~nu vrednost osteokalcina pre terapije (29,6 ± 3,343 ng/mL). Prose~na vrednost CTX I tri meseca nakon terapije tibolonom je bila ni`a (0,2870 ± 0,0783 ng/mL) u odnosu na prose~na vrednost CTX I pre te rapije (0,4539 ± 0,1144 ng/mL). Na{i rezultati pokazali su izrazito koristan uticaj tibolona na ko{tanu resorpciju i supresivni efekat na ko{tan...